SecBot SecBot
424B5 ·Filed Jul 27, 2026

PHGE

BiomX Inc.
BEARISH
Impact 7/10
Horizonimmediate Processed3mo ago SEC0001213900-26-081859
Actionable Insight ▼ Bearish

This ATM upsizing is a clear signal of acute capital needs. The massive potential dilution relative to market cap will likely drive further price erosion. Traders should expect continued downward pressure and avoid long positions. Monitor for rapid share issuance and further shelf takedowns.

DirectionBearish
Confidencehigh
Horizonimmediate

How the stock moved after the report

⚠ Clustered BEARISH VIEWSTOCK BELOW ENTRY AT T+20
Entry
$0.1834
T+0 close · Jul 27, 2026 · via day close
Latest settled
−26.39%
T+20 · $0.1350
Vs SPY
−29.77%
α at T+20
Next horizon
T+60
due 27d ago
  1. T+0 · Jul 28 $0.1834entry
  2. T+1 · 4mo ago −0.22%α +1.32% · $0.1830
  3. T+5 · 4mo ago +1.85%α −0.42% · $0.1868
  4. T+20 · 3mo ago −26.39%α −29.77% · $0.1350
  5. T+60 · due 27d ago Pending
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BiomX Inc. filed a prospectus supplement to its existing ATM offering agreement with H.C. Wainwright, updating the maximum aggregate offering price of common stock that may be sold under the shelf registration to $9.145 million. The company has already sold approximately $3.708 million under the program. With a market cap of only ~$2M and the stock trading at $0.1948, this represents massive potential dilution of over 450% of current market cap, signaling severe financial distress and a relentless need for cash.

Key Facts

  • BiomX filed a 424B5 prospectus supplement to sell up to $9,145,000 of common stock via an ATM agreement with H.C. Wainwright.
  • The company has already sold $3,708,127 under the ATM program prior to this supplement.
  • The stock closed at $0.1948 per share on the filing date, with a market cap of approximately $2 million.
  • The $9.145 million offering is over 4.5x the current market cap, implying extreme dilution.
  • The filing is the latest in a series of 12 offering/registration filings in the last 24 months, indicating persistent cash burn and reliance on dilutive financing.
  • The S-3 shelf (filed Feb 2026) was for resale of shares from a December 2025 PIPE and warrant exercise, adding further overhang.

Financial Impact

Up to $9.145 million in new common stock sales, representing ~457% of the current $2M market cap at $0.1948/share. Prior sales of $3.708M already executed.

dilutionmarket capshare price

Risk Factors

  • Extreme dilution from the ATM program could destroy remaining equity value.
  • Persistent cash burn and reliance on dilutive financing raise going-concern risk.
  • Low stock price and micro-cap status increase volatility and susceptibility to mechanical selling.

Market Snapshot

Exchange
NYSE
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
75% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
424B5 Filing (PHGE), Batch item 10001213900-26-081859
Document: 0001213900-26-081859-index-headers.html0001213900-26-081859
Document: 0001213900-26-081859-index.html0001213900-26-081859
Document: 0001213900-26-081859.txt0001213900-26-081859
424B5 Filing (PHGE), Batch item 50001213900-26-081859
Document: 0001213900-26-081859-index-headers.html0001213900-26-081859
Document: 0001213900-26-081859-index.html0001213900-26-081859
Document: 0001213900-26-081859.txt0001213900-26-081859

Track record

22 reports on PHGE

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +62.36% at T+20 after the Jun 16, 2026 report. 7 of 11 went positive at some point.

Filters
  1. Oct 7, 20265w ago 8-K Neutral 4/10 Entry $0.3092 to $0.2915 ▼ −5.72% −5.30% vs SPY
  2. Oct 7, 20265w ago DEF 14A Bearish 6/10 Entry $0.3092 to $0.2915 ▲ +5.72% +5.30% vs SPY
  3. Sep 1, 202610w ago 8-K Neutral 3/10 Entry $0.1425 to $0.1421 ▼ −0.28% −1.33% vs SPY
  4. Aug 28, 202611w ago 8-K Neutral 4/10 Entry $0.1371 to $0.1430 ▲ +4.30% +4.99% vs SPY
  5. Aug 5, 202614w ago Press Release Bearish 5/10 Entry $0.1800 to $0.1598 ▲ +11.22% +11.06% vs SPY
  6. Jul 28, 202615w ago 8-K Bearish 8/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
  7. Jul 28, 202615w ago Press Release Bearish 7/10 Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
  8. Jul 27, 202616w ago 424B5 Bearish 7/10 Viewing Entry $0.1834 to $0.1830 ▲ +0.22% −1.32% vs SPY
  9. Jul 8, 202618w ago Press Release Neutral 4/10 Entry $0.2758 to $0.2800 ▲ +1.52% +0.68% vs SPY
  10. Jul 2, 202619w ago 8-K Bearish 6/10 Entry $0.3190 to $0.3020 ▲ +5.33% +6.20% vs SPY
Showing 10 of 22

US Market Status

Market Closed · Opens in 4h 45m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 27, 2026